Deerfield Management Company »

Adma Biologics shares owned by Deerfield Management Company

Quarter-by-quarter ownership of Adma Biologics (ADMA) shares owned by Deerfield Management Company from 13F filings

Historical chart of Deerfield Management Company investment in Adma Biologics

Tip: Access up to 7 years of quarterly data

All positions including Adma Biologics held by Deerfield Management Company consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Adma Biologics by Deerfield Management Company

Quarter filed Position value Share count Share price at filing
2023-12-31 $193k 43k 4.52

More positions owned by Deerfield Management Company

Nuvalent Inc-a (NUVL)
Glaukos Corp Note 2.750% 6/1 (Principal)
Viatris (VTRS)
Invitae Corp Debt 4.500% 3/1 (Principal)
Natera Note 2.250% 5/0 (Principal)
Catalyst Pharmaceutical Partners (CPRX)
Centene Corporation (CNC)
Brookdale Sr Living Note 2.000%10/1 (Principal)
Insmed Note 1.750% 1/1 (Principal)
Neurocrine Biosciences (NBIX)
Accolade Note 0.500% 4/0 (Principal)
Oscar Health Cl A (OSCR)
Owens & Minor (OMI)
Adapthealth Corp Common Stock (AHCO)
Springworks Therapeutics (SWTX)

View all positions for Deerfield Management Company

Top funds holding Adma Biologics

Vanguard Group
D. E. Shaw & Co
Perceptive Advisors
AWM Investment Company
Dimensional Fund Advisors
Millennium Management
Assenagon Asset Management
Two Sigma Investments
Deutsche Bank Aktiengesellschaft
Two Sigma Advisers
Oberweis Asset Management
Goldman Sachs Group
Charles Schwab Investment Management
Bank of America Corporation
Tang Capital Management

View all funds holding Adma Biologics